Index appoints Johnson partner
02 September 2010
Index Ventures, the global high tech venture capitalist, has appointed Dr
Kevin Johnson
as a life sciences partner to enhance its push into developing asset-centric investment strategy. Dr Johnson,...
New investor leads Celator's $20 million series D
02 September 2010
Celator Pharmaceuticals has raised $20 million in a series D round led by new investor Thomas, McNerney & Partners.
Alex Zisson
, a partner at the venture capital firm, will join Celator's...
Scottish biotech companies combine
02 September 2010
Two Scottish university spin-out companies, ImmunoSolv and Grampian BioConsultants (GBC), have merged to combine their expertise in immunology and immuno-technology to avoid becoming a "one-trick...
Henderson Morley files notice of administration
02 September 2010
The small UK biotechnology firm Henderson Morley has filed a notice of intention to call in the administrators following its failure to secure the divestment of its ICVT (Ionic Contra Viral Therapy)...
India throws rule book at 'superbug' scientists
02 September 2010
Indian physicians who were involved in the controversial "superbug" NDM-1 study that was published in Lancet Infectious Diseases last month have been asked to confirm whether they followed various...
TiGenix outlines new market-focused strategy
02 September 2010
TiGenix, the Belgium based biotech that spunout its drug discovery activities last week, is focused on becoming a development and marketing company, its CEO
Gil Beyen
told Scrip.
The company spun...
Xeloda filed in Japan for additional gastric cancer use
02 September 2010
Roche's Japanese subsidiary, Chugai , has made an approval filing for Xeloda (capecitabine) for the treatment of advanced or refractory gastric cancer in patients who are not candidates for curative...